2025 Germany Adult Vaccine Market Revenue Opportunities Report
Description
The 2025 Germany Adult Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in Germany are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi S.A.. Pfizer leads with its broad portfolio including pneumococcal and COVID-19 vaccines such as COMIRNATY®, leveraging mRNA technology and extensive R&D networks. GSK excels with vaccines for herpes zoster (Shingrix), hepatitis, and influenza, focusing on adjuvants and recombinant technologies suited for aging adults. Merck is well-known for its HPV (Gardasil), pneumococcal, and MMR vaccines, emphasizing evidence-based development and public health partnerships. Sanofi has strong offerings in influenza and meningococcal vaccines, investing in innovative delivery platforms and expanding manufacturing capacity in the region.
In Germany's adult pneumococcal vaccine market specifically, Pfizer and Merck recently secured regulatory advances: Pfizer’s PREVENAR 20 and Merck’s CAPVAXIVE (the EU's first 21-valent conjugate for adults) are pivotal products. Sanofi is advancing its PCV21 candidate through late-stage trials. These companies dominate public and private sector vaccine procurement in Germany, where demand is rising due to demographic shifts and expanded vaccination recommendations for adults over 60. Their strategic manufacturing, regulatory authorizations, and established distribution channels support robust market presence and growth in Germany’s evolving adult immunization landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adult Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adult vaccine market in Germany are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi S.A.. Pfizer leads with its broad portfolio including pneumococcal and COVID-19 vaccines such as COMIRNATY®, leveraging mRNA technology and extensive R&D networks. GSK excels with vaccines for herpes zoster (Shingrix), hepatitis, and influenza, focusing on adjuvants and recombinant technologies suited for aging adults. Merck is well-known for its HPV (Gardasil), pneumococcal, and MMR vaccines, emphasizing evidence-based development and public health partnerships. Sanofi has strong offerings in influenza and meningococcal vaccines, investing in innovative delivery platforms and expanding manufacturing capacity in the region.
In Germany's adult pneumococcal vaccine market specifically, Pfizer and Merck recently secured regulatory advances: Pfizer’s PREVENAR 20 and Merck’s CAPVAXIVE (the EU's first 21-valent conjugate for adults) are pivotal products. Sanofi is advancing its PCV21 candidate through late-stage trials. These companies dominate public and private sector vaccine procurement in Germany, where demand is rising due to demographic shifts and expanded vaccination recommendations for adults over 60. Their strategic manufacturing, regulatory authorizations, and established distribution channels support robust market presence and growth in Germany’s evolving adult immunization landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
